ALK and non-small cell lung carcinoma: Targeted therapies have been developed against oncogenic drivers in NSCLC, such as mutations in epidermal growth factor receptor (EGFR), and gene rearrangement of anaplastic lymphoma kinase (ALK) and ROS oncogene 1 (ROS1).1, 3, 4